Mental and Behavioral Health

The panelists provide key takeaways from this discussion surrounding treatment-resistant depression.

Collaboration between providers and payers can help remove the stigmas associated with mental health disorders.

Michael Edward Thase, MD, leads a discussion surrounding an array of challenges impacting patients with treatment-resistant depression.

The panel of experts highlight the patient journey commonly experienced in search of a treatment-resistant depression diagnosis.

Panelists address factors driving clinical inertia in treatment-resistant depression.

Ms Maroney drives a conversation regarding response to treatment-resistant depression.

An in-depth assessment of treatment-resistant depression therapies is explored.

The panelists provide an overview of the treatment model for treating patients with treatment-resistant depression.

Key opinion leaders illustrate treatment strategies for patients diagnosed with TRD.

Medical experts discuss the risk factors associated with TRD.

The incidence and prevalence of TRD is explored.

Megan Maroney, PharmD, BCPP, leads a discussion about the treatment landscape of TRD.

Pharmacogenetic testing and therapeutic drug monitoring are feasible in the inpatient psychiatric treatment setting.

Survey respondents indicated a lack of comfort around recommending psilocybin therapy to patients.

How can current Alzheimer disease treatments be used to best treat patients living with the disease?

There was a lower probability of initiating psycholeptics and experiencing postpartum psychiatric emergencies in study patients who continued using antidepressants

Developing innovative solutions for women with depression, accounting for differences in gender and sex, are critically important

A recent CDC report detailed the increased rates of sadness and violence among teenage girls.

United States leaders work together to create bipartisan solutions for the youth mental health crisis.

The relationship between dermatology and social media was analyzed in a poster presentation during SBS 2023 in Miami, Florida.

Zuranolone, a fast-acting neuroactive steroid that can take effect in 14 days, has been assigned a PDUFA action date of Aug. 5, 2023 by the FDA. It can be used to treat patients with major depressive disorder and postpartum depression.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

There may not be a diagnosis for ‘New Year Depression,’ but about 10% to 20% of individuals in the US may get a milder form of these winter blues.

A recent study found a rise in the prevalence of antipsychotic prescriptions among pediatric patients and noted which antipsychotics were most commonly used for specific indications.